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Reversal of hyperparathyroidism in response to dietary phos-
phorus restriction in the uremic dog. The role of phosphorus in
the genesis of uremic hyperparathyroidism is well established.
Prophylactic reduction of dietary phosphorus intake (PRS-P) in
exact proportion to GFR reduction prevents renal hyperparathy-
roidism, but its effects on established hyperparathyroidism,
serum calcium and phosphate concentration, and phosphorus
balance are not known. Seven chronically uremic dogs (2 to
5 months) were housed in metabolic cages and maintained on a
controlled phosphorus intake of 1,200 mg/day. After a control
period of 10 days, the dogs were subjected to PRS-P. Control
GFR averaged 16 4 mllmin; serum phosphate concentration
(Se), 4.3 0.2 mg/dl; serum ionized calcium concentration
4.67 0.29 mg/di; parathyroid hormone level (PTH), 610 91 pi
Eq/mi; and 24-hr urine phosphate excretion (U04V), 845 84
mg. During PRS-P, no change in GFR or S occurred (17 mI/mm
and 4.3 mg/dl, respectively). Sica increased significantly by day 2
and plateaued by day 4 at 5.13 0.20 mg/dl. PTH fell progres-
sively over the 16 days of PRS-P to 170 49 pd Eq/mi. Upo4V
fell on day 1 of PRS-P and plateaued by day 2. Stool phosphorus
excretion averaged 43% of intake. Total phosphorus excretion
(urine plus stool) did not differ significantly from measured in-
take. Tubular maximum phosphate reabsorptionlGFR averaged
2.7 0.4 mg/lOO ml before PRS-P and increased significantly to
4.9 0.2 mg/tOO ml after 18 days of PRS-P. In summary, dietary
therapy with PRS-P appears to be an effective method, not only
for preventing uremic hyperparathyroidism, but for reversing es-
tablished uremic hyperparathyroidism. In view of the growing
evidence that PFH may be a major "uremic toxin," PRS-P could
represent an important element in the future therapy of chronic
renal failure.
Reversion de I'hyperparathyroidisme en réponse a Ia restriction
alimentaire de phosphate cnez le chien urémique. Le role du phos-
phore dans Ia génése de i'hyperparathyroidisme est bien étabii.
La reduction prophylactique de l'apport alimentaire de phos-
phore (PRS-P) dans La méme proportion que celie du debit de
filtration glomerulaire empéche i'hyperparathyroidisme mais
son effet sur l'hyperparathyroidisme installé, sur les concentra-
tions plasmatiques de calcium et de phosphore et sur le bilan de
phosphore, ne sont pas connus. Sept chiens urémiques chro-
niques (2 a 5 mois) ont été installés dans des cages metaboliques
et maintenus a un apport de 1200 mg de phosphore/jour. Après
une période contrôie de 10 jours les chiens ont été soumis a
PRS-P. Le debit de filtration glomérulaire pendant Ia période
contrOle était de 16 4 mi/mm; le phosphate plasniatique (Si.) de
4,3 0,2 mg/dl; le calcium ionisé du plasma (Sica) de 4,67 0,29
mg/di; l'hormone parathyroidienne (PTH) de 610 91 jl . Eq/
ml; l'excrétion urinaire quotidienne de phosphate (U04V) de 845
43
84 mg. Pendant PRS-P GFR et S n'ont pas été modifies (17
mllmin et 4,3 mgldl, respectivement). 5Ica a augmente signifi-
cativement a partir du 2ème jour pour atteindre un plateau au
4ème, a 5,13 0,20 mg/di. La PTH a diminué progressivement
pendant les i6jours de PRS-Pjusqu'a 170 49 sl Eq/mi. Up4V
a diminué des le premier jour jusqu'au plateau atteint le 2ème
jour. L'excrétion fécale de phosphore a été de 43% de I'apport.
L'excrétion totale de phosphore (urine et selies) n'était pas sig-
nificativement différente de l'apport mesuré. La reabsorption
tubulaire maximum de phosphate/GFR était en moyenne de 2,7
0,4 mg/100 ml avant PRS-P et a augmenté significativement a
4,9 0,2 mg/100 ml aprês i8jours. En résumé, PRS-P paraIt une
méthode efficace non seulement pour empécher i'hyperparathy-
roidisme mais aussi pour obtenir sa reversion. Du fait de l'ac-
cumulation des preuves que Ia PTH est une toxine urémique,
PRS-P pourrait étre un élément important dans le traitement
futur de i'insuffisance rénale chronique.
As kidney function declines during the course of
chronic progressive renal disease, the need for
maintaining phosphorus homeostasis is met by an
everincreasing rate of phosphate excretion per
nephron [1-4]. It has been proposed that this physi-
ologic adaptation, which contributes importantly to
life maintenance, may account also, at least in part,
for the hyperparathyroidism of uremia [5].
In the dog and rat, it has been possible to obviate
prophylactically the need for an ever-increasing
fractional excretion of phosphate as renal function
declines by reducing dietary phosphorus in exact
proportion to the fall in GFR [6-9]. This dietary
therapy is associated with the maintenance of nor-
mal parathyroid hormone (PTH) levels over a peri-
od of many months.
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The possibility that a dietary regimen may ob-
viate uremic hyperparathyroidism is of more than
academic interest. There is mounting evidence that
PTH may represent an important "uremic toxin"
with adverse effects that go beyond the bone dis-
ease [10-241. The present study was designed to
evaluate the effects of reducing dietary phosphorus
intake in exact proportion to the fall in GFR on PTH
levels, serum calcium and phosphate concentration,
and phosphorus balance in the chronically uremic
dog with established uremic hyperparathyroidism.
More specifically, does it lead to reversal of hyper-
parathyroidism; and does this dietary therapy trade
osteitis fibrosis cystica for negative phosphorus bal-
ance (and thus increase the risk of osteomalacia)?
Methods
Seven adult female mongrel dogs (weight range,
13 to 18 kg) were made uremic by ligation of the
majority of the branches of the left renal artery and
removal of the right kidney. Three of the animals
were studied during the third month and four during
the sixth month of experimental uremia.
From the initiation of uremia, the dogs received
400 g of a fibrin-base low phosphorus diet (ICN
Pharmaceuticals, Cleveland, Ohio) daily, to which
1,200 mg of phosphorus as neutral sodium phos-
phate (designated as "constant solute intake", CSI)
was added. The daily intake of calcium was 1,700
mg, and that of magnesium was 240 mg. The pro-
tocol was as follows: The dogs, which as indicated
were chronically uremic, were transferred to indi-
vidual metabolic cages but maintained on the 1,200
mg/day phosphorus intake for a control period of 10
days. Thereafter, their phosphorus intake was
"proportionally" reduced using the formula: 1,200
mg x GFR uremialGFR initial. Both values for
GFR were measured, the "uremia" value during
the 10-day control period and the "initial" value
prior to the induction of renal insufficiency. Phos-
phorus intake thereby was reduced in exact propor-
tion to the measured reduction in GFR (designated
as "proportional reduction of solute-phosphorus",
PRS-P). Body weight in all dogs remained stable
throughout the metabolic study.
Urine collections were begun and terminated at
the same time each day. A single feeding by oro-
gastric intubation was given at 2:00 P.M. Blood sam-
ples were collected anaerobically at 9:00 A.M. from
an anterior limb vein. Three-day stool collections
were performed during the second week of phos-
phorus reduction. Carmine (Alum Lake, Fisher
Scientific), 0.6 g, was given as an intermittent stool
marker 72 hours apart. All stool specimens were col-
lected from the first apperance of the dye up to but
not including the second appearance of the dye [25].
In four dogs, phosphate titration studies were
performed at the beginning of the 10-day control pe-
riod while they were on the CSI regimen and again
after they had been on the PRS-P regimen for 18
days. The titration studies were done in the morning
with the animals in the unanesthetized state, stand-
ing in a supporting sling, and fasted overnight. They
had free access to water until the time of the experi-
ment. A urinary catheter was inserted into the blad-
der for quantitative urine collection. Venous cath-
eters were placed in the inferior vena cava through
a hind limb vein for infusion and blood sampling.
After injection of a priming dose of creatinine, a so-
lution of 0.45% saline containing creatinine was in-
fused at a rate of 0.3 mllmin.
After a 60-mm period of equilibration, three 20-
mm control clearance periods were obtained.
Thereafter, a solution of neutral sodium phosphate
(Na3HPO4, 44 g/liter; NaH2PO4, 10.7 g/liter) was in-
fused at a rate of 0.4 mllmin. Eight 30-mm clearance
periods then were obtained. At the midpoint of each
period, a sample of blood was collected. At the end
of each period, the bladder was washed with 30 ml
of sterile water to ensure complete urine collection.
The 72-hour stool collections were blended with
distilled water to a fixed volume. Duplicate l0-ml
aliquots were alkalinized to a pH of 10 with 3 N so-
dium carbonate and dried at 1000 C for 24 hours.
The samples were then ashed at 615° C for 24 hours.
The ash was digested with 10 ml of concentrated
hydrochloric acid for 24 hours. The digest was then
made up to 50 ml with distilled water and analyzed.
Phosphate and creatinine were measured by a
modified autoanalyzed method (Technicon Auto
Analyzer II). Serum ionized calcium was deter-
mined with a flow-through electrode system (Orion
Biomedical, model SS-20). Serum PTH was quan-
titated by radioimmunoassay using antiserum CH-
71 at a final dilution of 1:125,000 [5, 2611. This anti-
serum cross-reacts with intact hormone as well as
NH2- and COOH-terminal fragments. Each sample
was measured in duplicate at two widely varying di-
lutions. The coefficient of variation of replicate as-
says was 9%; samples showing a larger variation
were reassayed. PTH levels are reported in arbi-
trary units (d . Eq/ml), relating the potency of the
test serum to that of a standard hyperparathyroid
serum obtained from a dog with experimentally in-
duced chronic renal failure.
Data are expressed as means SEM. Statistical
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Table 1. Serum and urine values during constant solute intake (CSI)
(PRSP)a
and 16 days of proportional reduction of solute-phosphorus
During CS!
During PRS-P
Day 2 Day 4 Day 7 Day 9 Day II Day 14 Day 16
GFR,ml/min
Sre ,mg/dl
S,,mg/d1
UV,mg/duy
PTH,.d Eq/mi
26 4
4.3 0.2
4.67 0.29
845 84
610 9!
14 3
4.2 0.4
5.O1 0.17
l77 35
504 112
13 2
4.0 0.2
5.13e 0.20
135k 40
4l5 104
17 4
4.0 0.4
5.l5 0.18
t57 50
375 104
16 3
4.3 0.3
S.22 0.04
1l2 II
31ff 97
19 4
4.0 0.3
5.22k 0.20
t02' IS
267 91
17 4
4.1 0.3
S.24 0.15
t37 20
234 78
17 4
4.3 0.2
5.l9 0.14
l38 22
17ff 49
Values are the mean SEM for 7 dogs. Abbreviations are serum phosphate concentration; S, serum ionized calcium concentration; 24-hour urine phosphate
excretion; and PTH, parathyroid hormone level.
Significantly different from control value (P < 0.05)
Significantly different from control and preceeding value (P < 0.05)
analyses were performed with standard programs
for Student's t tests for paired and unpaired data on
a Wang 700 calculator.
Results
Before producing experimental uremia, the mean
normal GFR was 84 mI/mm. Table 1 shows the
mean values for GFR, serum phosphate and serum
ionized calcium concentrations, 24-hour urinary
phosphate excretion rates, and PTH levels during
the control period on the CS! regimen and during a
16-day period on the PRS-P regimen. GFRs re-
mained stable throughout, averaging 16 4 mllmin
during the control period and 17 4 mllmin on day
16 of the PRS-P therapy.
Serum phosphate concentrations averaged 4.3
0.2 mIld! during CSI and did not change significant-
ly over the 16 days of PRS-P.
When the dogs were on CSI, their serum ionized
calcium values averaged 4.67 0.29 mg/dl. After
only 2 days of PRS-P, the mean value had risen sig-
nificantly to 5.01 0.17 mg/dl, and the value contin-
ued to rise significantly through day 4, at which time
it plateaued at 5.13 0.20 mg/dl.
With 1,200 mg of phosphorus per day, urinary
phosphate excretion was 845 84 mg/day. With
PRS-P, phosphate excretion fell within 1 day and
plateaued by day 2.
All dogs had marked hyperparathyroidism before
the PRS-P regimen was initiated. The mean PTH
level during the control period was 610 91 pJ . Eq/
ml with a range of 300 to 900 pi . Eq/ml (normal
range, 40 to 100 l Eq/ml). PTH levels fell steadily
and significantly each day over the 16 days of PRS-
P to 170 49 l Eq/ml. By the 16th day of study,
four dogs had normal PTH levels, but the remaining
three dogs had values which were somewhat ele-
vated. These three dogs had the highest PTH levels
at the outset.
Table 2 presents the phosphate balance data of
six dogs obtained during the second week of the
PRS-P regimen. Stool and urine phosphate excretion
averaged 43 6% and 53 6% of intake, respec-
tively. For the group, total excretion (urine plus
feces) was not significantly different from intake.
The results of the phosphate titration studies are
shown in Table 3. The values for tubular maximum
reabsorption of phosphate per GFR (Tm04/GFR)
are derived at a steady-state serum phosphate con-
centration between 8 and 10 mg/dl. During CSI, the
Tm04/GFR averaged 2.7 0.4 mg/tOO ml. After 18
days of PRS-P, the Tm04/GFR had increased signif-
icantly to 4.9 0.2 mg/100 ml.
Table 2. Three-day phosphorus balance while on proportiona1 reduction of solute-phosphorus (PRS-P)
.
Dietary
phosphorus
Stool phosphate Urinary phosphate
— Total
excretion% of% of
mg/72 hr mg172 hr intake mg172 hr intake mg172 hr
540 154 29 380 70 534
540 191 35 383 71 574
600 196 33 243 41 439
900 637 71 317 35 954
630 231 37 299 47 530
720 365 51 388 54 753
Mean
SEM 655 56 296 74 43 6 335 24 53 6 631 77
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Table 3. Tm04/GFR (mg/100 ml) during CSI and after 18 days of
PRSPa
CS! PRS-P
2.9 4.7
1.8 4.7
3.6 5.5
2.5 4.6
Mean
SCM 2.7 04b 4.9 0.2
a See Table 1 for abbreviations.
b Significantly different from PRS (P < 0.001)
Discussion
Hyperparathyroidism is an almost universal con-
comitant of chronic renal failure [201. Although the
etiology of uremic hyperparathyroidism is multi-
factorial, the role of dietary phosphorus appears to
be well established [5—9].
The sequence of events may be an exaggerated
hyperphosphatemia after eating, causing prolonged
hypocalcemia with subsequent sustained stimula-
tion of PTH secretion [9, 271. It has also been sug-
gested that phosphate may limit the production of
1,25 dihydroxycholecalciferol [28]. The low con-
centration of this active metabolite of vitamin D in
uremia is at least partially responsible for the im-
paired intestinal calcium absorption of chronic renal
failure and the skeletal resistance to exogenous
PTH [20, 21].
The dog with experimental uremia manifests ure-
mic hyperparathyroidism similar to the patient with
chronic renal failure [5]. The uremic hyperpara-
thyroid animal has been shown to develop skeletal
changes of increased osteoclastic reabsorptive
surface area within 6 months of the induction of re-
nal failure [8]. This skeletal abnormality correlated
with the concentration of circulating PTH. It has
been possible to largely prevent uremic hyper-
parathyroidism [6-9] and parathyroid-induced bone
disease [8] in the experimental animal by prophylac-
tically decreasing dietary phosphorus intake in ex-
act proportion to the decrease in GFR at the in-
ception of renal insufficiency. Whether this dietary
therapy can reverse the established hyperparathy-
roidism of advanced chronic renal insufficiency is
an important question for patient management.
A major theoretical limitation of a low-phos-
phorus diet would be the development of phosphate
depletion with all its adverse effects. Previous stud-
ies with PRS-P have not dealt with this question,
but hypophosphatemia has not been observed. Re-
cently, animals with PRS-P have been shown to
have physiologic responses inconsistent with phos-
phate depletion. The phosphaturic response to ex-
ogenous PTH is exaggerated in the uremic rat [29]
and dog [30]. Phosphate depletion, in contrast, is
associated with a blunted response [31, 32]. In the
uremic dog, a phosphorus load is excreted similarly
whether the diet is CSI or PRS-P [9]. In contrast,
phosphate depletion is associated with a blunted
phosphaturia following a phosphorus load [33, 34].
The present study shows that external phosphorus
balance is well maintained throughout the period of
PRS-P. The percentage of absorbed dietary phos-
phorus in the present animals is in good agreement
with those observed in more extensive studies in
uremic man on higher phosphorus intake [21]. A
study of uremic man on a low-protein (and thus low-
phosphorus) diet, showed negative phosphorus bal-
ance but is not comparable because of the protein
restriction [35].
Previous studies have suggested that a slight but
significant increase in the concentration of serum
ionized calcium develops in the uremic dog treated
with PRS-P [9, 30]. The development of this rise in
serum ionized calcium concentration is clearly
documented in this study. The value for serum ion-
ized calcium was significantly elevated by day 2 of
PRS-P, and increased further through day 4, and re-
mained elevated thereafter. The cause of the hyper-
calcemia is unclear, but it is not caused by phos-
phate depletion. It could conceivably relate to the
change in calcium:phosphorus product in the diet
making more calcium available for absorption. An-
other more likely possibility would be a change in
hormonal status due to PRS-P. A reduction in phos-
phorus intake is known to increase 1,25 dihydroxy-
cholecalciferol production in the normal state [28].
It is conceivable that PRS-P increased this vitamin
D analog and thus calcium absorption.
PTH levels in each dog fell progressively during
the period of PRS-P. By the 16th day of study, four
dogs had normal PTH levels, but the remaining
three dogs' values were still somewhat elevated.
There is a clear dissociation between the rapid de-
cline in urinary phosphate excretion and the pro-
tracted fall in PTH levels. These parameters cannot
be compared because of the nature of the PTH as-
say which measures both NH2- and COOH-terminal
fragments. Many of these PTH metabolites have a
prolonged half-life in uremic dog and man [36-40].
The major observation, though, is that the estab-
lished hyperparathyroidism of uremia is reversible
by PRS-P.
Tm04/GFR was low, as expected, when the dogs
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were on the CSI regimen with high levels of circu-
lating PTH [9, 30]. After 18 days of PRS-P, when
the circulating levels of PTH had by and large re-
turned to normal, the Tmp04/GFR had risen signifi-
cantly to values similar to those reported previously
in a prophylactic PRS-P protocol and similar to lev-
els found in normal dogs [9, 30]. Although the level
of parathyroid activity may be implicated in the
change in Tm04/GFR [41], other data suggest that
dietary phosphorus intake itself can reset the level
of tubular reabsorption [34]. The present experi-
mental design can not differentiate these factors.
In summary, dietary therapy with PRS-P appears
to be a potential method for reversing established
uremic hyperparathyroidism, although the degree
of chronicity is probably critical as evidenced by
the slowness of regression of hyperparathyroidism
in many patients following successful renal trans-
plantation. In a preliminary report, PRS-P has been
shown to reverse uremic hyperparathyroidism in
patients with mild chronic renal failure [42]. In the
present short-term studies, PRS-P is associated
with the maintenance of phosphate balance and
with the return of PTH levels to or towards the nor-
mal range. With the evolving evidence that impli-
cates PTH as a major "uremic toxin," PRS-P may
represent an important future therapeutic modality,
as well as a major experimental investigative tool.
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